Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial

TEAMM Trial Management Group and Trial Investigators, Mark T Drayson, Stella Bowcock, Tim Planche, Gulnaz Iqbal, Guy Pratt, Kwee Yong, Jill Wood, Kerry Raynes, Helen Higgins, Bryony Dawkins, David Meads, Claire T Hulme, Irene Monahan, Kamaraj Karunanithi, Helen Dignum, Edward Belsham, Jeff Neilson, Beth Harrison, Anand LokareGavin Campbell, Michael Hamblin, Peter Hawkey, Anna C Whittaker, Eric Low, Janet A Dunn

Research output: Contribution to journal › Article › peer-review

34 Citations (Scopus)

455 Downloads (Pure)

34 Citations
1 Article

1 results

2019

Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT
Drayson, M. T., Bowcock, S., Planche, T., Iqbal, G., Pratt, G., Yong, K., Wood, J., Raynes, K., Higgins, H., Dawkins, B., Meads, D., Hulme, C. T., Whittaker, A. C., Hawkey, P., Low, E. & Dunn, J. A., Nov 2019, In: Health Technology Assessment. 23, 62, p. 1-94
Research output: Contribution to journal › Article › peer-review

Open Access
File

2 Citations (Scopus)

142 Downloads (Pure)

Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial

Research output

Search results

Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT